Shares of Curevac rose 10% in premarket trading on Friday. Shares of the German biotech have lost 48% this week after the company said a late-stage clinical trial of its COVID-19 vaccine was only 47% effective . But Curevac’s chief financial officer, Pierre Kemula, said the company hopes its candidate can still be of use, when a final analysis is done, with that data just two or three weeks away. “We need to look at the data and see, OK, what would be the best value, how we can place this vaccine to make this available,” he told the Financial Times in an interview. Curevac uses the same messenger RNA technology as the COVID-19 vaccines developed by Pfizer and German partner BionNTech and Moderna , which have shown efficacy greater than 90% and have already been distributed to millions worldwide.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.